These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38963658)

  • 1. Patterns of brain metastases response to immunotherapy with pembrolizumab.
    Mahajan A; Goldberg SL; Weiss SA; Tran T; Singh K; Joshi K; Aboian MS; Kluger HM; Chiang VL
    J Neurooncol; 2024 Sep; 169(3):555-561. PubMed ID: 38963658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
    Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
    J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
    Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
    Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
    Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
    Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A
    Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
    Fantoni A; Warburton L; Solomon B; Alexander M; Maddula M; Brown LJ; da Silva IP; Nagrial A; Abu Al-Hial F; Itchins M; Pavlakis N; Bowyer S
    Clin Lung Cancer; 2024 Jul; 25(5):449-459. PubMed ID: 38705835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for non-small cell lung cancer with central nervous system metastases: A two-case report.
    Di M; Zhang L
    Thorac Cancer; 2019 Feb; 10(2):381-385. PubMed ID: 30614652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
    Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
    Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
    Goldberg SB; Schalper KA; Gettinger SN; Mahajan A; Herbst RS; Chiang AC; Lilenbaum R; Wilson FH; Omay SB; Yu JB; Jilaveanu L; Tran T; Pavlik K; Rowen E; Gerrish H; Komlo A; Gupta R; Wyatt H; Ribeiro M; Kluger Y; Zhou G; Wei W; Chiang VL; Kluger HM
    Lancet Oncol; 2020 May; 21(5):655-663. PubMed ID: 32251621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
    Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
    Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
    Maity A; Mick R; Huang AC; George SM; Farwell MD; Lukens JN; Berman AT; Mitchell TC; Bauml J; Schuchter LM; O'Hara M; Lin LL; Demichele A; Christodouleas JP; Haas NB; Patsch DM; Hahn SM; Minn AJ; Wherry EJ; Vonderheide RH
    Br J Cancer; 2018 Nov; 119(10):1200-1207. PubMed ID: 30318516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
    Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
    Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.
    Tran TT; Mahajan A; Chiang VL; Goldberg SB; Nguyen DX; Jilaveanu LB; Kluger HM
    J Immunother Cancer; 2019 Jul; 7(1):200. PubMed ID: 31362777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
    Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
    Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G
    Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2020 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.